During the past decade, Tanenbaum Dermatology Center conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 2 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 2 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Tanenbaum Dermatology Center" are "Dermatitis, Atopic" (2 trials) and "Atopic Dermatitis" (1 trials). Many other conditions were trialed in "Tanenbaum Dermatology Center" in a lesser frequency.

Most popular intervention types in "Tanenbaum Dermatology Center" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Abrocitinib 100 mg" (1 trials), "Abrocitinib 200 mg" (1 trials), "PF-04965842 100 mg" (1 trials) and "PF-04965842 200 mg" (1 trials). Other intervention names were less common.

The vast majority of trials in "Tanenbaum Dermatology Center" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Tanenbaum Dermatology Center". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Tanenbaum Dermatology Center, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Tanenbaum Dermatology Center, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".